Sign up for our free daily newsletter
YOUR PRIVACY - PLEASE READ CAREFULLY DATA PROTECTION STATEMENT
Below we explain how we will communicate with you. We set out how we use your data in our Privacy Policy.
Global City Media, and its associated brands will use the lawful basis of legitimate interests to use
the
contact details you have supplied to contact you regarding our publications, events, training,
reader
research, and other relevant information. We will always give you the option to opt out of our
marketing.
By clicking submit, you confirm that you understand and accept the Terms & Conditions and Privacy Policy
The Financial Times reports that the Dublin-headquartered firm’s study came as Royalty Pharma launched its $6.6bn bid for Irish drug company Elan, while just last week Canadian life insurer Great-West Lifeco bid €1.3bn for Ireland’s biggest life insurer Irish Life - which was nationalised during the financial crisis.
Propel activity
William Fry noted that a stream of potential deals in the pharmaceutical, medical and biotechnology sectors this year will further propel M&A activity in Ireland in 2013.
‘Overseas buyers are not only focused on distress-driven opportunities. With its improved competitiveness, Ireland’s future within the euro is more certain than it was a year or two ago,’ said the firm in its report.
The study also revealed that the value of mergers and acquisitions completed in Ireland increased 18 per cent to €17.1bn in 2012.
Email your news and story ideas to: [email protected]